EU Agrees on Critical Medicines Act to Boost Domestic Production

The legislation responds to widespread shortages experienced during the coronavirus pandemic when panic buying and disrupted supply chains left pharmacies and hospitals struggling to obtain critical treatments. Under the new framework, measures will be introduced to incentivise companies to manufacture key medicines within the bloc rather than depending on imports from outside regions.

The act forms part of a broader strategy to improve resilience in pharmaceutical supply chains. Officials expect the legislation to reduce vulnerability to future global disruptions.

During the pandemic, many member states faced acute shortages of medicines ranging from antibiotics to intensive care drugs. Hospitals reported rationing supplies while patients experienced delays in treatment. The agreement marks the latest step in efforts to enhance preparedness for health emergencies.

By prioritising domestic manufacturing capacity, the legislation aims to ensure more stable supplies during periods of heightened demand or international trade restrictions.